|
|
Volumn 58, Issue 3, 2006, Pages 347-349
|
|
Drug-eluting stents: Beyond the hyperbole
|
|
Author keywords
Cypher; Drug eluting stents; Restenosis; TAXUS
|
|
Indexed keywords
BIOMEDICAL ENGINEERING;
COSTS;
DRUG THERAPY;
METALS;
TOXIC MATERIALS;
CYPHER;
DRUG-ELUTING STENTS;
RESTENOSIS;
TAXUS;
DRUG PRODUCTS;
ANTIINFECTIVE AGENT;
IMMUNOSUPPRESSIVE AGENT;
METALLOPROTEINASE INHIBITOR;
PACLITAXEL;
POLYMER;
RAPAMYCIN;
STEROID;
ARTERY INTIMA PROLIFERATION;
ARTICLE;
CLINICAL PRACTICE;
CLINICAL TRIAL;
CORONARY ARTERY BYPASS SURGERY;
CORONARY ARTERY DISEASE;
CORONARY ARTERY THROMBOSIS;
CORONARY STENT;
COST OF ILLNESS;
DRUG DELIVERY SYSTEM;
DRUG ELUTING STENT;
ECONOMIC ASPECT;
HEALTH CARE COST;
HEART MUSCLE REVASCULARIZATION;
HUMAN;
NONHUMAN;
OPEN HEART SURGERY;
PATHOPHYSIOLOGY;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REIMBURSEMENT;
RESTENOSIS;
RISK ASSESSMENT;
RISK FACTOR;
TRANSLUMINAL CORONARY ANGIOPLASTY;
TREATMENT FAILURE;
TREATMENT INDICATION;
TREATMENT OUTCOME;
|
|
EID: 33744516942
PISSN: 0169409X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.addr.2006.01.013 Document Type: Note |
|
Times cited : (19)
|
|
References (0)
|
